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Abstract
Background: Inadequate liver regeneration (LR) is still an unsolved problem in major liver resection and small-for-size
syndrome post-living donor liver transplantation. A number of microRNAs have been shown to play important roles in cell
proliferation. Herein, we investigated the role of miR-26a as a pivotal regulator of hepatocyte proliferation in LR.
Methodology/Principal Findings: Adult male C57BL/6J mice, undergoing 70% partial hepatectomy (PH), were treated with
Ad5-anti-miR-26a-LUC or Ad5-miR-26a-LUC or Ad5-LUC vector via portal vein. The animals were subjected to in vivo
bioluminescence imaging. Serum and liver samples were collected to test liver function, calculate liver-to-body weight ratio
(LBWR), document hepatocyte proliferation (Ki-67 staining), and investigate potential targeted gene expression of miR-26a
by quantitative real-time PCR and Western blot. The miR-26a level declined during LR after 70% PH. Down-regulation of
miR-26a by anti-miR-26a expression led to enhanced proliferation of hepatocytes, and both LBWR and hepatocyte
proliferation (Ki-67
+ cells %) showed an increased tendency, while liver damage, indicated by aspartate aminotransferase
(AST), alanine aminotransferase (ALT) and total bilirubin (T-Bil), was reduced. Furthermore, CCND2 and CCNE2, as possible
targeted genes of miR-26a, were up-regulated. In addition, miR-26a over-expression showed converse results.
Conclusions/Significance: MiR-26a plays crucial role in regulating the proliferative phase of LR, probably by repressing
expressions of cell cycle proteins CCND2 and CCNE2. The current study reveals a novel miRNA-mediated regulation pattern
during the proliferative phase of LR.
Citation: Zhou J, Ju W, Wang D, Wu L, Zhu X, et al. (2012) Down-Regulation of microRNA-26a Promotes Mouse Hepatocyte Proliferation during Liver
Regeneration. PLoS ONE 7(4): e33577. doi:10.1371/journal.pone.0033577
Editor: Shree Ram Singh, National Cancer Institute, United States of America
Received September 21, 2011; Accepted February 14, 2012; Published April 4, 2012
Copyright:  2012 Zhou et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by the National High Technology Research and Development Program of China (863 Program) (2012AA021008), the Key
Clinical Project from the Ministry of Health (2010159), National Natural Science Foundation of China (30972951 and 81170448), and special fund for science
research by Ministry of Health (201002004). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the
manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: rockyucsf1981@126.com (ZG); gdtrc@126.com (XH)
. These authors contributed equally to this work.
Introduction
After 70% partial hepatectomy (PH) in mice, the residual liver is
unique in its intrinsic ability to regenerate to restore its original
mass and function within 7–10 days in a process called liver
regeneration (LR) [1–6]. Despite there are massive studies of LR,
many aspects of this process remain still unknown, for example,
the elegant genetic regulation of hepatocytes proliferation.
MicroRNAs (miRNAs) are a class of small RNAs regulating gene
expression by degrading messenger RNAs via binding to their 39-
untranslated regions (39-UTRs). MiRNAs have been reported to
modulate a variety of biological processes, including cell differenti-
ation, proliferation, metabolism, apoptosis and even carcinogenesis
[7–11].SeveralstudieshaveshownthecriticalroleofmiRNAsinliver
regeneration.SongGSetalreportedthatmiR-378playscriticalroles
during the early phase of LR by directly inhibiting the expression of
Odc1,whichisassociatedwithDNAsynthesis[12–13].Furthermore,





role of miR-26a in hepatocyte proliferation during LR. In our
preliminary study, using a quantitative real-time PCR analysis, we
found that, like miR-378, miR-26a expression was obviously down-
regulated in regenerating mice liver tissue at 120 h after 70% PH,
compared with the sham operation (SH) group. We therefore
hypothesized that down-regulation of miR-26a might promote
hepatocyte proliferation duringLR.
In the current study, we showed evidences that miR-26a
expression is remarkably declined during LR after PH, and that
down-regulation of this miRNA could promote hepatocyte
proliferation in vivo. MiR-26a may regulate LR by repression of
cell cycle proteins CCND2 and CCNE2. This study provides a
novel mechanism and potential therapeutic target of miRNA
regulation of hepatocyte proliferation during LR.
Materials and Methods
Animals
A total of 120 healthy male C57BL/6J mice (purchased from
the Animal Center of Sun Yat-sen University, Guangzhou, China),
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e33577aged 8–10 weeks and weighing 21–25 g, were housed (2–4 mice
per cage) in an animal room under specific pathogen-free
conditions with 2262.0uC indoor temperature and a 12-hour
light/dark cycle, and had free access to water and standard chow.
All animal experiments were performed in a humane manner, and
in accordance with the Institutional Animal Care Instructions.
The study protocol was approved by the Ethics Committee for
Animal, Sun Yat-sen University (approval ID: 2010 NO.9).
Vector Construction
Firstly, LUC and IRES were cloned into a pShuttle-CMV
vector (Agilent Technologies, USA), and then pri-miR-26a
sequences or anti-miR-26a sequences were introduced into the
pShuttle-CMV-IRES-LUC vector (Agilent Technologies, USA).
The pShuttle-CMV-IRES-LUC vector after linearization with
PmeI and pAdWasy-1 (Agilent Technologies, USA) was recom-
bined into pAdEasy-IRES-LUC vector. Next, a 293AD cell line
(Cell Biolabs, San Diego, USA) [18], was transfected with
pAdEasy-IRES-LUC vector, and then, liquid supernatant includ-
ing viral particles was isolated and collected. The viral particles
including Ad5-miR-26a-LUC vector, Ad5-anti-miR-26a-LUC
vector, were established.
Transfection Efficiency Assessment
The Ad5-miR-26a-LUC vector and Ad5-anti-miR-26a-LUC
vector were diluted to different concentrations of 4610
10 IU/mL,
4610
8 IU/mL and 4610
6 IU/mL with PBS, respectively. Each
vector was transfected to mice. Three days later, the liver tissue
was collected to test the expression of miR-26a by real time PCR.
Surgical Procedure
Forty animals were randomly divided into two groups (n=20 in
each group) as follows: (1) In PH group, 70% PH was performed
under anesthesia with isoflurane as described by Mitchell et al [4].
In brief, the left lateral, median liver lobes were surgically removed
after laparotomy. (2) In SH group, the abdomen of mice was
opened but no liver resection was performed. In the functional
study, 80 mice undergoing 70% PH, were randomly assigned to
four groups (n=20 in each group) as follows: (1) In Ad5-anti-miR-
26a-LUC (AA) group, animals were treated with Ad5-anti-miR-
26a-LUC vector (0.5 mL, 4610
10 IU/mL) via portal vein. (2) In
Ad5-miR-26a-LUC (AM) group, animals were treated with Ad5-
miR-26a-LUC vector (0.5 mL, 4610
10 IU/mL) via portal vein. (3)
In Ad5-LUC (AL) group, animals were treated with Ad5-LUC
empty vector (0.5 mL, 4610
10 IU/mL) via portal vein. (4) In
control group, animals only received 70% PH but with no
transfection. At the indicated time points (24 h, 72 h, 120 h, 168
h after resection), the mice were sacrificed and the residual liver
specimens and blood samples were collected for analysis.
In vivo Bioluminescence Imaging
At 24h or 72 h after transfection, mice from the AA group
(n=5), AM group (n=5), AL group (n=5) and control group
(n=5), were subjected to in vivo bioluminescence imaging [19–24].
Briefly, the animals, anaesthetized by isoflurane as described
previously [4], were intraperitoneally injected with D-luciferin
(Biotium, USA) in a concentration of 150 mg/Kg, and 20 minutes
later, were subjected to the in vivo bioluminescence imaging using
the system of photobiology (Zhongke, China).
Liver-to-body Weight Ratio
At the indicated time points, the animals were sacrificed. The
total body weight was measured and the remnant and regenerated
liver tissues were resected and weighed. The acquired data were
expressed as percentage of the ratio between remnant liver weight
(A), divided by the total body weight (B) times 100 (liver-to-body
weight ratio [LBWR] (%)=A/B6100).
Liver Function Tests
Mice were sacrificed and blood samples were collected via the
postorbital venous plexus. Blood serum was sampled and analyzed
for aspartate aminotransferase (AST), alanine aminotransferase
(ALT), and total bilirubin (T-Bil) using methods as described [25].
Immunohistochemical Staining and Evaluation
Mice liver tissues were collected at the indicated time points
from the AA group, AM group, AL group and control group.
Immunostaining for Ki-67, a marker for cell proliferation, was
performed to evaluate the proliferation of hepatocytes according to
the manufacture’s guidelines. The primary antibody was a rabbit
monoclonal anti-mouse/rat/human Ki-67 antigen (DCS Diag-
nostics, Germany). Immunohistochemistry was performed using a
biotin-free enhanced polymer one-step staining technique (EPOS-
method) with a peroxidase-conjugated polymer backbone coupled
with a goat anti-rabbit secondary antibody (Dako, Germany).
‘‘Proliferation index’’ was defined as the percentage of Ki-67
positive cells randomly counted in five high-power fields (6400) of
each specimen.
Quantitative Real-time PCR (qRT-PCR)
Total RNA was extracted from prepared liver samples with
Trizol (Invitrogen, Carlsbad, USA) reagent and cDNA was
synthesized according to the manufacturer’s protocol (MBI
Fermentas). Quantitative RT-PCR was performed using a
standard SYBR Green PCR Master Mix (Toyobo, Osaka, Japan),
and PCR-specific amplification was conducted in the Applied
Biosystems (ABI7500) real-time PCR machine. The relative
expression of genes (miR-26a, U6, CCND2, CCNE2, CCNE1,
CDK6, CCND1, CCND3, and b-actin) was calculated with the 2-
(DDCt) method [26]. The primers used are listed in Table 1.
Western Blot Analysis
For whole protein extracts, liver tissue samples after grinding
were homogenized in lysis buffer (Promega, USA), incubated for
30 minutes on ice, then centrifuged for 15 min at 140006g. Prior
to use, all buffers were treated with a protease inhibitor cocktail
(Konchem, China). Equal amounts of protein were separated
discontinuously on 12–15% SDS-PAGE and transferred to a
PVDF membrane (Millipore, USA). The antibodies employed
included anti-CCND2 (Santa cruz, USA), anti-CCNE2 (Santa
cruz, USA), anti-CCNE1 (Santa cruz, USA), anti-CDK6 (Santa
cruz, USA), anti-CCND1 (Santa cruz, USA), anti-CCND3 (Santa
cruz, USA) and b-actin (Kangcheng, China). Immunoblots were
developed using anti-mouse- or anti-rabbit-HRP secondary
antibodies (Dako, CA), followed by detection with immobilon
western chemilimunescent HRP substrate (Millipore, USA)
according to the manufacturer’s instructions. For all western
blots, b-actin was used as a reference gene.
Statistical Analysis
All data are expressed as mean 6 standard deviation. The
statistical analysis was performed by one-way analysis of variance.
A P value of less than 0.05 was considered to be statistically
significant.
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Down-regulated miR-26a Expression During LR
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compared to SHgroup (P,0.01) (Figure1).
Transfection Efficiency and Analysis of in Vivo
Bioluminescence Imaging
To assess transfection efficiency of vector in vivo, we measured
miR-26a expression in mice transfected with Ad5-anti-miR-26a-
LUC, Ad5-miR-26a-LUC or Ad5-LUC vector. The miR-26a
expressions after transfection with Ad5-anti-miR-26a-LUC in
concentrations of 4610
10 IU/mL (A1), 4610
8 IU/mL (A2) and
4610
6 IU/mL (A3) were decreased compared with control group
(1.0260.07 vs. 1.3660.08, P,0.001; 1.0860.02 vs. 1.3660.08,
P,0.001; 1.1460.04 vs. 1.3660.08, P,0.01). Similar results in
A1, A2 and A3 group were observed compared with Ad5-LUC
group (1.0260.07 vs. 1.2760.06, P,0.01; 1.0860.02 vs.
1.2760.06, P,0.01; 1.1460.04 vs. 1.2760.06, P,0.05)
(Figure 2A). In contrast, increased miR-26a expression after
transfection with Ad5-miR-26a-LUC in concentration of 4610
10
IU/mL (M1) was observed compared with control group
(1.8460.14 vs. 1.3660.08, P,0.01). Likely, significant difference
can also be seen between sub-group M1 and Ad5-LUC group
(1.8460.14 vs. 1.2760.06, P,0.001) (Figure 2B). In addition,
there is no significant difference between Ad5-LUC group and
control group. Besides, the in vivo bioluminescence imaging
technology was used to verify that Ad5-anti-miR-26a-LUC (AA),
Ad5-miR-26a-LUC (AM) and Ad5-LUC (AL) have been success-
fully transfected into the liver of C57BL/6J mice. At 24 h after
transfection, the area of bioluminescence in each group showed no
obvious difference (Fig. S1). And at 72 h after transfection, because
of the different size of regenerated liver masses, the area of
bioluminescence was obviously different (Figure 2C, D, E), and the
mice in control group showed no bioluminescence (Figure 2F).
Impacts of miR-26a Transfection on LBWR in C57BL/6J
Mice after 70% PH
To investigate the impacts of miR-26a on regulating LR after
70% PH in C57BL/6J mice, we assessed the LBWR after
70% PH. We observed a higher LBWR (2.2260.35%) in AA
group compared with AL group (1.8660.11%) at 72 h after
transfection (P,0.05). Likely, at 120 h and 168 h after
transfection, higher LBWRs were also observed in AA than AL
group (3.0860.17% vs. 2.6460.08%, P,0.001; 3.2260.21% vs.
2.7260.1%, P,0.001), and reverse results were obtained between
AM group and AL group (120 h: 2.2260.17% vs. 2.6460.08%,
P,0.001; 168 h: 2.3860.08% vs. 2.7260.1%, P,0.01). The
LBWR of control group were 1.6460.05%, 2.0060.14%,
2.6860.08% and 2.7660.13%, respectively, at 24 h, 72 h, 120
h and 168 h after 70% PH. In addition, there were no statistical
differences between control group and AL group at all time points.
The LBWRs in different groups were shown in Figure 3A.
Impact of miR-26a Transfection on Hepatocyte
Proliferation after 70% PH
As expected, the increase of liver mass was accompanied by a
corresponding increase of the Ki-67 proliferation index (PI). After
transfection, a significant increase of the Ki-67 PI was seen in AA
group when compared with AL group (24 h: 54.9060.98% vs.
50.6061.26%, P,0.001; 72 h: 69.4861.35% vs. 58.7261.71%,
P,0.001; 120 h: 22.2661.09% vs. 16.1661.18%, P,0.001; and
168 h: 23.6861.49% vs. 14.360.63%, P,0.001). In contrast, a
significant decrease was observed in AM group in comparison with
AL group (24 h: 46.8260.95% vs. 50.6061.26%, P,0.001; 72 h:
36.8060.94% vs. 58.7261.71%, P,0.001; and 120 h:
9.3060.75% vs. 16.1661.18%, P,0.001). The Ki-67 PI of
control group was 51.7061.58%, 59.7861.55%, 16.6061.11%
and 14.2260.93%, respectively, at 24 h, 72 h, 120 h and 168 h























Figure 1. Down-regulation of miR-26a during LR. The expression
of miR-26a in the regenerating liver from 24 h to 168 h after 70% PH
was assessed by qRT-PCR analysis. MiR-26a levels were standardized to
that of U6. All data were obtained from at least three independent
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between control group and AL group at all time points. The Ki-67
PIs in different groups were shown in Figure 3B.
Impact of miR-26a Transfection on Liver Function Tests
after 70% PH
To assess liver cell injury after transfection, we accessed plasma
liver function including AST, ALT and T-Bil. More serious liver
damage was documented in AM group than in AL group (shown
in Figure 3C, D, E). In addition, there was no statistical difference
between control group and AL group at all time points.
CCND2 and CCNE2 but not CCNE1, CDK6, CCND1 or
CCND3 are Potential Targeted Genes of miR-26a
To investigate the mechanism through which miR-26a
modulates the cell cycle of proliferative phase of liver cells, we
examined putative targets of miR-26a using algorithms including
Targetscan, miRanda, and PicTar [27–29]. These analysis predict
that miR-26a may regulate cyclin D2 (CCND2), cyclin E1
(CCNE1), cyclin E2 (CCNE2), and cyclin dependent kinase 6
(CDK6), all of which play an important role in cell cycle [30].
Quantitative real-time PCR and western blotting were used to
determine whether miR-26a regulates any of these putative targets
in vivo. Both CCND2 and CCNE2 expression in AA group were
notably enhanced in both mRNA (Figure 4A) and protein level
(Figure 4B). In contrast, they were remarkably decreased in AM
group. However, the CCNE1 and CDK6 expression showed no
apparent change in both mRNA (Figure 4A) and protein level
(Figure 4B). The CCND1 and CCND3 expression in AA group
and AM group showed no obvious change in both mRNA
(Figure 4C) and protein level (Figure 4D) compared with AL
group. In addition, there is no significant difference between
control group and AL group. Furthermore, the CCND2, CCNE2,
CDK6 and CCNE1 expression in vitro in both mRNA and protein
level also supported the in vivo findings (Fig. S2). Together, these
results suggest that CCND2 and CCNE2 but not CCNE1, CDK6,
CCND1 or CCND3 are potential targeted genes of miR-26a.
Discussion
Loss of liver mass triggers a regenerative response in the whole
liver. Liver tissue loss may occur as a result of partial liver
resection, living donor liver transplantation, reduced size liver
transplantation, toxic injury, exposure to viruses and trauma. If
LR fails to give a prompt and sufficient response to the loss, the
patients would die off liver failure [31]. Although there are
evidences that several miRNAs are involved in LR [12,32–34],
little is known about how these miRNAs regulate the proliferative
phase of LR. Recent studies showed that miR-26a is down-
regulated in breast cancer and nasopharyngeal carcinoma [35,36],
indicating that it is a pivotal miRNA regulating cell proliferation.
Importantly, miR-26a could inhibit cancer cell growth in human
liver cancer [15]. Our preliminary study using qRT-PCR analysis
has found that miR-26a was sharply down-regulated in the
regenerating liver tissues at 120 h following 70% PH compared
with SH group in mice. In the present study, we further confirmed
that miR-26a was obviously down-regulated during the prolifer-
ative phase of LR.
LR is a timely sequence of events consisting of priming phase,
proliferation/expansion phase, and termination phase [37]. As
expected, the LBWR increased gradually as the residual live mass
increased, while the proliferation rate reached its peak at 36–72 h
post-PH. Importantly, we found that miR-26a was down-regulated
before 24 h post-PH, suggesting miR-26a may be a negative
regulator of LR and took part in the regulation of LR at the very
beginning. And we also demonstrated that over-expression of
miR-26a could suppress the hepatocyte proliferation in LR.
Together with the previous study [15], this study proved that miR-
Figure 2. Transfection efficiency and in vivo bioluminescence
imaging. (A) Expression of miR-26a after transfection with different
concentrations of Ad5-anti-miR-26a-LUC, Ad5-LUC, or no transfection
(control). (B) Expression of miR-26a after transfection with different
concentrations of Ad5-miR-26a-LUC, Ad5-LUC, or no transfection
(control). The degree of bioluminescence was the greatest in Ad5-
anti-miR-26a-LUC (AA) group (C), less in Ad5-LUC (AL) group (E), and the
weakest in Ad5-miR-26a-LUC (AM) group (D). The mice in control group
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proliferation during LR and cancer cell growth in liver
carcinogenesis.
Undoubtedly, hepatocyte proliferation during LR requires
active cell cycle progression. Cell cycle progression itself is
regulated by cyclin expression and activation of cyclin-dependant
kinases (CDKs) [37]. And the algorithms analysis predicts that
miR-26a may regulate CCND2, CCNE1, CCNE2, and CDK6. It
is well known that the D-type cyclins (D1, D2, and D3) play key
roles in cell cycle machinery, and these cyclins positively regulate
cell proliferation by binding to CDK4 and CDK6, resulting in the
phosphorylation of the retinoblastoma protein and the G1/S
transition of the cell [38]. As well, it is widely acknowledged that
CCNE2 and CCNE1 are critically required for normal prolifer-
ation of virtually all mammalian cell types, especially in controlling
transition of quiescent cells into cell cycle progression [39]. Herein,
Figure 3. Anti-miR-26a expression promotes liver regeneration and improves liver function in mice. (A) LBWR of mice transfected with
Ad5-anti-miR-26a-LUC (AA), Ad5-miR-26a-LUC (AM) and Ad5-LUC (AL). There was an increased LBWR in AA group compared to AL group (P,0.001),
and a decreased LBWR in AM group can be seen compared with AL group at 120 h (P,0.001). (B) The Ki-67 proliferation index (PI) after 70% PH and
transfection, was significantly higher in AA group compared with AL group (P,0.001), while lower in AM group in comparison with AL group
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CCND2 and CCNE2, and conversely, anti-expression of miR-26a
leads to an enhanced expression of CCND2 and CCNE2 in both
mRNA and protein level in vivo, suggesting CCND2 and CCNE2
are probably the targeted genes of miR-26a. Together, miR-26a
down-regulation probably regulates hepatocyte proliferation
through enhancing CCND2 and CCNE2 expression. Under-
standing how miR-26a targets CCND2 and CCNE2 may provide
detailed mechanism by which miR-26a regulates hepatocyte
proliferation during LR.
There are a number of methods, such as placenta extract [40],
platelet [41], and carbon monoxide [42], have been shown to
promote LR in animal studies. However, none of these methods
have been translated into clinical practice because of their low
safety and efficacy. MiRNAs, as potent post-transcriptional
regulators of gene expression, offer hopes of novel therapeutic
targets for enhanced LR [43]. Of course, although the data are
interesting, there are several limitations in this study. Firstly, the
detailed molecular mechanism by which miR-26a regulates
CCND2 and CCNE2 is still to be elucidated. In addition, how
miR-26a may affect the two major LR pathway, namely IL-6 and
hepatocyte growth factors (HGF) pathways, is unkown. These
limitations provide room for future study.
In conclusion, we report for the first time that miR-26a plays
crucial roles in regulating the proliferative phase of LR. These
results show that miR-26a may regulate LR by repressing the
expression of CCND2 and CCNE2. This study sheds lights on the
mechanism by which miR-26a regulates LR during PH and may
act as a therapeutic target in the future.
Supporting Information
Figure S1 Transfection reliability and in vivo biolumi-
nescence imaging. The area of bioluminescence was scarcely
different among AA group (A), AM group (B) and AL group (C) at
24 h after transfection, suggesting that transfection efficiency
among three groups was similar. The control group (no
transfection) showed no bioluminescence image (D).
(TIF)
Figure S2 CCND2 and CCNE2 are potential targeted
genes of miR-26a in Nctc-1469 mouse liver cells. (A) Anti-
miR-26a expression increased the mRNA expression of CCND2
and CCNE2 as shown by qRT-PCR. Conversely, miR-26a over-
expression declined the mRNA expression of these two genes. The
mRNA expression of CCNE1 and CDK6 showed no obvious
change. (B) Anti-miR-26a expression up-regulated the protein
expression of CCND2 and CCNE2. In contrast, miR-26a over-
expression down-regulated the protein expression of CCND2 and
CCNE2. (C) The protein expression of CCNE1 and CDK6





Figure 4. CCND2 and CCNE2 are potential targeted genes of miR-26a. (A) Anti-miR-26a expression increased the mRNA expression of
CCND2 and CCNE2 as shown by qRT-PCR. Conversely, miR-26a over-expression declined the mRNA expression of the two genes. The mRNA
expression of CCNE1 and CDK6 showed no obvious change. (B) Anti-miR-26a expression up-regulated the protein expression of CCND2 and CCNE2.
In contrast, miR-26a over-expression down-regulated the protein expression of CCND2 and CCNE2. The protein expression of CCNE1 and CDK6
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